To further build upon its drug research and development capabilities, NeurOp has formed consulting relationships with a number of experts in neuropharmacology, drug chemistry, toxicology, and pre-clinical and clinical studies. Our scientific and clinical advisors regularly consult with us on research programs, the design of our studies, and a variety of scientific and technical issues.
Daniel Laskowitz, M.D.
Dr. Laskowitz is an associate professor of medicine in the Duke University School of Medicine Division of Neurology. He treats SAH patients and has designed and participated in clinical trials for new therapeutics for SAH and other ischemic indications. Dr. Laskowitz is assisting NeurOp in planning the clinical development of its drugs for the treatment of ischemic indications, including SAH and cognitive deficit after bypass surgery.
Pre-Clinical & Clinical Development Team
Michael Dalton, Pharm.D.
Dr. Dalton is a founding partner of The Gnomon Group, LLC, a consulting company that provides regulatory and drug safety services to the pharmaceutical industry. He has more than 30 years’ experience in the pharmaceutical industry working with large companies, small start-ups, and contract research organizations.
John Dillberger, D.M.V., Ph.D.
Dr. Dillberger is a toxicologist who has worked for GlaxoSmithKline, Triangle Pharmaceuticals, and Argolyn Biosciences. He is currently a consultant and has been involved in numerous evaluations of novel chemical entities and regulatory submissions to the FDA.
Andrea True Kelly, Ph.D.
Dr. True Kelly served a pivotal role in creating and managing several clinical programs at Trimeris for both Fuzeon® (enfuvirtide) and the IND filing and clinical trials of its next-generation fusion inhibitor, TRI-1144. Her degree is in pharmacology.